Molecularly targeted therapies for advanced prostate cancer include castration modalities
that suppress ligand-dependent transcriptional activity of the androgen receptor (AR) …

Purpose: Prostate cancer is the second leading cause of male cancer deaths. Castration-
resistant prostate cancer (CRPC) is a lethal stage of the disease that emerges when …

Persistent androgen receptor (AR) transcriptional activity underlies resistance to AR-
targeted therapy and progression to lethal castration-resistant prostate cancer (CRPC) …

While there are myriad mechanisms of primary and acquired resistance to conventional and
next-generation hormonal therapies in prostate cancer, the potential role of androgen …

Prostate cancer (PC) remains a leading cause of cancer-related deaths among men
worldwide, despite continuously improved treatment strategies. Patients with metastatic …

Androgen depletion for advanced prostate cancer (PCa) targets activity of the androgen
receptor (AR), a steroid receptor transcription factor required for PCa growth. The …

In the last few years, the survival of patients with castration-resistant prostate cancer (CRPC)
has significantly improved as a result of the development of second-generation androgen …

Advanced prostate cancer (PCa) treated with androgen deprivation therapy (ADT)
eventually relapses to an ADT-resistant disease referred to as castration-resistant PCa …

Constitutively active androgen receptor splice variants (AR-V) lacking the ligand-binding
domain have been implicated in the pathogenesis of castration-resistant prostate cancer …

Background The androgen receptor (AR) is a key prostate cancer drug target. Suppression
of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing …